Bayer

Biomarkers

• HER2 (ERBB2) activating mutation3
• MSI-H / dMMR3
• KRAS G12C1
• KRAS G12D1
• NTRK1/2/3 fusion1

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

pembrolizumab 4sevabertinib 3VVD-133214 2larotrectinib 1cetuximab 1sotorasib 1trametinib 1bevacizumab 1

Trials

10 of 21 trials shown

1. A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

   Recruiting Phase 3 Bayer Started 2024Primary completion 2027-10 NCT06452277

   sevabertinib FDApembrolizumabcisplatincarboplatinpemetrexed

   Documented activating HER2 mutation in the tyrosine kinase domain (TKD) assessed by tissue molecular test in a CLIA-certified…

   HER2 (ERBB2) activating mutationAdvanced Non-small Cell Lung Cancer, HER2 Mutation

2. A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum

   Recruiting Phase 2 Bayer Started 2026Primary completion 2028-06 NCT07811193

   VVD-133214pembrolizumab FDA EU

   Have a known microsatellite instability (MSI) and/or deficient mismatch repair (dMMR) tumor status confirmed per local standard o…

   MSI-H / dMMRColorectal Adenocarcinoma

3. A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

   Recruiting Phase 2 Bayer Started 2025Primary completion 2029-02 NCT06760819

   sevabertinib FDA

   Documented activating HER2 mutation

   HER2 (ERBB2) activating mutationAdvanced Solid Tumors, HER2 Mutation

4. First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

   Recruiting Phase 1/2 Bayer Started 2021Primary completion 2028-12 NCT05099172

   sevabertinib FDA

   Documented activating EGFR and/or HER2 mutation assessed by a Clinical Laboratory Improvement Amendments (CLIA)-certified (United States …

   HER2 (ERBB2) activating mutationAdvanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation

5. A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children

   Active, not recruiting Phase 1/2 Bayer Started 2015Primary completion 2024-07 NCT02637687

   larotrectinib FDA EU

   OR Infants from birth and older with a diagnosis of malignancy and with a documented NTRK fusion that has progressed or was nonresponsive to available therapies, and for which no standar…

   NTRK1/2/3 fusionSolid Tumors Harboring NTRK Fusion

6. A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation

   Recruiting Phase 1 Bayer Started 2026Primary completion 2029-07 NCT07535112

   BAY 3771249cetuximab

   KRAS G12D mutated solid tumor

   KRAS G12DAdvanced/Metastatic Colorectal Adenocarcinoma

7. A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

   Recruiting Phase 1 Bayer Started 2025Primary completion 2027-08 NCT06804824

   VVD-159642sotorasibtrametinib

   any solid tumor that harbors an epidermal growth factor receptor (EGFR) alteration as per local/historical testing

   EGFR exon 19 deletion / L858RAdvanced Solid Tumors

8. A Phase I Study of BAY3498264 Given Together With Sotorasib in Participants Who Have Advanced Solid Cancers With Specific Genetic Changes Called KRASG12C Mutation

   Recruiting Phase 1 Bayer Started 2024Primary completion 2027-04 NCT06659341

   BAY3498264

   Histologically confirmed solid tumor malignancy with documented KRAS\^G12C mutation as assessed by an appropriately accredited laboratory.

   KRAS G12CAdvanced Solid Tumors Harboring KRAS G12C Mutation

9. A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors

   Recruiting Phase 1 Bayer Started 2024Primary completion 2027-05 NCT06004245

   VVD-133214pembrolizumab FDA EUbevacizumab

   Have a microsatellite instability (MSI) and/or deficient mismatch repair (dMMR), histologically or cytologically documented…

   MSI-H / dMMRAdvanced Solid Tumors, Colorectal Cancer

10. A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

    Recruiting Phase 1 Bayer Started 2023Primary completion 2030-08 NCT05954312

    VVD-130037docetaxelpaclitaxelpembrolizumab FDA EU

    …eckpoint inhibitor (for tumors with known programmed death-ligand 1 \[PD-L1\] expression, microsatellite instability-high, or mismatch repair deficiency, and an anti-epidermal growth factor receptor agent) (Comb…

    MSI-H / dMMRAdvanced Solid Tumors

No trials match these filters.